收费全文 | 20599篇 |
免费 | 1537篇 |
国内免费 | 82篇 |
耳鼻咽喉 | 168篇 |
儿科学 | 596篇 |
妇产科学 | 338篇 |
基础医学 | 2707篇 |
口腔科学 | 256篇 |
临床医学 | 2513篇 |
内科学 | 5215篇 |
皮肤病学 | 686篇 |
神经病学 | 1959篇 |
特种医学 | 740篇 |
外国民族医学 | 3篇 |
外科学 | 2838篇 |
综合类 | 181篇 |
一般理论 | 17篇 |
预防医学 | 1261篇 |
眼科学 | 325篇 |
药学 | 1199篇 |
中国医学 | 25篇 |
肿瘤学 | 1191篇 |
2023年 | 109篇 |
2022年 | 166篇 |
2021年 | 500篇 |
2020年 | 265篇 |
2019年 | 421篇 |
2018年 | 513篇 |
2017年 | 353篇 |
2016年 | 394篇 |
2015年 | 487篇 |
2014年 | 666篇 |
2013年 | 847篇 |
2012年 | 1331篇 |
2011年 | 1430篇 |
2010年 | 749篇 |
2009年 | 711篇 |
2008年 | 1136篇 |
2007年 | 1161篇 |
2006年 | 1110篇 |
2005年 | 1077篇 |
2004年 | 999篇 |
2003年 | 915篇 |
2002年 | 878篇 |
2001年 | 420篇 |
2000年 | 447篇 |
1999年 | 390篇 |
1998年 | 198篇 |
1997年 | 182篇 |
1996年 | 140篇 |
1995年 | 116篇 |
1994年 | 116篇 |
1993年 | 114篇 |
1992年 | 270篇 |
1991年 | 253篇 |
1990年 | 190篇 |
1989年 | 235篇 |
1988年 | 219篇 |
1987年 | 215篇 |
1986年 | 224篇 |
1985年 | 214篇 |
1984年 | 168篇 |
1983年 | 158篇 |
1982年 | 113篇 |
1981年 | 85篇 |
1979年 | 132篇 |
1978年 | 110篇 |
1976年 | 93篇 |
1975年 | 121篇 |
1974年 | 107篇 |
1973年 | 112篇 |
1971年 | 91篇 |
Methods: The affinity of CNS 7056 and its carboxylic acid metabolite, CNS 7054, for benzodiazepine receptors and their selectivity profiles were evaluated using radioligand binding. The activity of CNS 7056 and midazolam at subtypes ([alpha]1[beta]2[gamma]2, [alpha]2[beta]2[gamma]2, [alpha]3[beta]2[gamma]2, [alpha]5[beta]2[gamma]2) of the [gamma]-aminobutyric acid type A (GABAA) receptor was evaluated using the whole cell patch clamp technique. The activity of CNS 7056 at brain benzodiazepine receptors in vivo was measured in rats using extracellular electrophysiology in the substantia nigra pars reticulata. The sedative profile was measured in rodents using the loss of righting reflex test.
Results: CNS 7056 bound to brain benzodiazepine sites with high affinity. The carboxylic acid metabolite, CNS 7054, showed around 300 times lower affinity. CNS 7056 and CNS 7054 (10 [mu]m) showed no affinity for a range of other receptors. CNS 7056 enhanced GABA currents in cells stably transfected with subtypes of the GABAA receptor. CNS 7056, like midazolam and other classic benzodiazepines, did not show clear selectivity between subtypes of the GABAA receptor. CNS 7056 (intravenous) caused a dose-dependent inhibition of substantia nigra pars reticulata neuronal firing and recovery to baseline firing rates was reached rapidly. CNS 7056 (intravenous) induced loss of the righting reflex in rodents. The duration of loss of righting reflex was short (< 10 min) and was inhibited by pretreatment with flumazenil. 相似文献
Data Sources/Study Setting. The data represent the population of all Medicare+Choice (M+C) plans offered to Medicare beneficiaries in the United States in 1999.
Study Design. The dependent variable is the log of the ratio of the market share of the j th health plan to the lowest cost plan in the beneficiary's county of residence. The explanatory variables are measures of premiums and benefits in the j th health plan relative to the premiums and benefits in the lowest cost plan.
Data Collection Methods. The data are from the 1999 Medicare Compare database, and M+C enrollment data from the Centers for Medicare and Medicaid Services (CMS).
Principal Findings. A $10 increase in an M+C plan's out-of-pocket premium, relative to its competitors, is associated with a decrease of four percentage points in the j th plan's market share (i.e., from 25 to 21 percent), holding the premiums of competing plans constant.
Conclusions. Although our price elasticity estimates are low, the market share losses associated with small changes in a health plan's premium, relative to its competitors, may be sufficient to discipline premiums in a competitive market. Bidding behavior by plans in the Medicare Competitive Pricing Demonstration supports this conclusion. 相似文献